THE WOODLANDS, TX — March 5, 2026 — Leads & Copy — Autonomix Medical, Inc. (NASDAQ: AMIX) announced today that its presentation, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026.
The presentation will be delivered by Chief Executive Officer Brad Hauser on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET in the International Ballroom – West. CRT is one of the world’s leading educational forums for interventional cardiovascular medicine.
The CRT Best Innovation Competition highlights transformative technologies with the potential to impact patient care. According to Autonomix, selection for oral presentation reflects the program’s emphasis on scientific innovation, technical differentiation and clinical relevance.
“Being selected for CRT’s Best Innovation Competition is a strong validation of our precision-guided, transvascular approach to interrogating and treating the nervous system,” said Brad Hauser, CEO of Autonomix. “Our technology is designed to provide physicians with unprecedented insight into peripheral nerve signaling.”
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies.
The company believes this will enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. Autonomix is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer.
The company notes that pancreatic cancer is a condition that causes debilitating pain and is without a reliable solution. According to Autonomix, its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. The technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit Autonomix’s website and connect with the Company on X, LinkedIn, Instagram and Facebook.
Source: Autonomix Medical, Inc.
